Scientists race to develop vaccine as Bundibugyo Ebola outbreak grows

4,449 cases had been reported in the DRC by August 12, placing the Bundibugyo strain at the centre of an urgent international vaccine effort. Researchers have moved several candidates into human trials after compressing development work that normally takes years into a matter of weeks.

The outbreak is centred in eastern Democratic Republic of Congo, where health teams are working to identify infections, isolate patients and limit transmission through contact with bodily fluids. Ebola can cause severe fever, internal and external bleeding, and organ failure. The virus spreads through close contact with infected people or contaminated materials, making health facilities, households and burial practices critical points of response.

The human cost is already severe. WHO Director-General Tedros Adhanom Ghebreyesus said 2,061 people had died and 886 had recovered by the August 12 reporting date. Images from Bunia, in Ituri Province, have shown Red Cross and Red Crescent teams preparing burials, while hygiene workers disinfect people entering the Rwampara Ebola Treatment Centre.

For neighbouring countries, continued transmission raises the possibility of cross-border spread. Every week without an effective Bundibugyo countermeasure increases the pressure on surveillance systems and frontline workers across the region.

Bundibugyo has no approved vaccine or treatment, setting this outbreak apart from epidemics caused by the Zaire strain. Licensed vaccines and treatments exist for Zaire Ebola, but those tools cannot simply be assumed to protect people against a different virus strain.

That gap has shaped the scientific response. Researchers and manufacturers are testing several candidates, with the first human trials now under way. The trials must generate evidence about safety and immune responses while the outbreak continues, a difficult timetable for regulators, study teams and communities already dealing with illness and loss.

Rachael Bonawitz, who leads CEPI’s Filovirus Disease Programme, described the effort as a race against time. The phrase reflects a practical problem: vaccine protection arrives only after candidates have been designed, manufactured, tested and delivered. A candidate that reaches a trial quickly still needs careful monitoring before health authorities can determine how it should be used.

The response also depends on local participation. Trial recruitment, contact tracing and infection control require trust in health authorities and clear communication with communities. Researchers must work alongside Congolese health teams rather than treating the outbreak solely as a laboratory challenge.

CEPI has committed more than $60 million to a portfolio of Bundibugyo vaccine candidates, giving researchers and manufacturers resources to work at outbreak speed. The money addresses a problem that has long weakened preparedness for rare infectious diseases: companies face high development costs and no dependable market once an outbreak fades.

Bonawitz said sporadic outbreaks leave vaccine developers without reliable demand, guaranteed buyers or predictable financial returns. That uncertainty can discourage manufacturers from maintaining production capacity for diseases that may sit dormant for years.

CEPI and Gavi, the Vaccine Alliance, launched a financing strategy in June that combines so-called push and pull mechanisms. Push funding supports research and development before a product exists. Pull incentives are designed to create a clearer prospect of demand and procurement if a vaccine meets agreed requirements. The source does not disclose the value of each individual incentive.

CEPI’s broader commitment to epidemic preparedness stood at $22.7 million, equivalent to CHF 18.2 million, between 2022 and 2026, supported by private investors, philanthropy and states including Switzerland. The Geneva connection matters. Gavi is headquartered in Geneva, and Switzerland’s role in international health financing places its institutions and taxpayers close to decisions about which threats receive sustained attention.

2,061 deaths had been reported by August 12, while 886 patients had recovered without specific Bundibugyo therapies or vaccines. Those figures capture both the lethality of the outbreak and the work of clinical teams providing supportive care under difficult conditions.

Ebola treatment centres must protect staff while caring for patients with severe disease. Workers use protective clothing, manage controlled access and disinfect surfaces and equipment. Burial teams face particular risks because bodies can remain infectious after death. Safe burials must respect families and local customs while reducing exposure to mourners and funeral workers.

The outbreak’s trajectory will depend on more than vaccine supply. Health authorities need rapid testing, reliable reporting, trained staff and the ability to trace contacts across densely connected communities. Armed conflict, population movement and limited access to healthcare can complicate each of those tasks in eastern Congo, although the source does not quantify their individual effects in this outbreak.

Vaccines could strengthen that response, especially if trials establish protection quickly enough to support targeted vaccination around cases or among frontline workers. Until then, infection prevention, clinical care and community cooperation remain the principal tools available to contain transmission.

Switzerland is linked to the response through Geneva’s global health institutions and support for CEPI, while the immediate work remains in Congolese communities and treatment centres. The outbreak demonstrates why preparedness funding is judged over years, not only during the weeks when cases accelerate.

WHO, Gavi and CEPI operate from Geneva and coordinate with governments, research groups, donors and manufacturers around the world. Their decisions can influence whether a promising vaccine candidate receives enough financing to enter trials, whether production capacity is maintained and whether doses can reach affected countries quickly.

The current effort will produce evidence beyond Bundibugyo. Researchers will learn how rapidly a vaccine platform can be adapted to a lesser-known Ebola strain, how trials can be organised during transmission and which financing commitments help manufacturers move before a market exists. Those lessons may shape responses to other epidemic threats.

For Swiss policymakers, the episode also puts a familiar question in concrete terms: whether international health contributions should fund preparedness before a crisis reaches Europe. The answer will be measured in research capacity, manufacturing readiness and agreements that can deliver vaccines while an outbreak is still containable. In eastern DRC, those preparations are being tested now.